Selective Enhancement of Tonic GABAergic Inhibition in Murine Hippocampal Neurons by Low Concentrations of the Volatile Anesthetic Isoflurane

Volatile (inhaled) anesthetics cause amnesia at concentrations well below those that cause loss of consciousness and immobility; however, the underlying neuronal mechanisms are unknown. Although many anesthetics increase inhibitory GABAergic synaptic transmission, this effect occurs only at high con...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of neuroscience Vol. 24; no. 39; pp. 8454 - 8458
Main Authors Caraiscos, Valerie B, Newell, J. Glen, You-Ten, Kong E, Elliott, Erin M, Rosahl, Thomas W, Wafford, Keith A, MacDonald, John F, Orser, Beverley A
Format Journal Article
LanguageEnglish
Published United States Soc Neuroscience 29.09.2004
Society for Neuroscience
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Volatile (inhaled) anesthetics cause amnesia at concentrations well below those that cause loss of consciousness and immobility; however, the underlying neuronal mechanisms are unknown. Although many anesthetics increase inhibitory GABAergic synaptic transmission, this effect occurs only at high concentrations (>100 μ m ). Molecular targets for low concentrations of inhaled anesthetics have not been identified. Here, we report that a tonic inhibitory conductance in hippocampal pyramidal neurons generated by α5 subunit-containing GABA A receptors is highly sensitive to low concentrations of the volatile anesthetic isoflurane (ISO) (25 and 83.3 μ m ). The α5 subunit is necessary for enhancement of the tonic current by these low concentrations of isoflurane because potentiation is absent in neurons from α5 -/- mice. Furthermore, ISO (25 μ m ) potentiated recombinant human α5β3γ2L GABA A receptors, whereas this effect was not seen with α1β3γ2L GABA A receptors. These studies suggest that an increased tonic inhibition in the hippocampus may contribute to amnestic properties of volatile anesthetics.
AbstractList Volatile (inhaled) anesthetics cause amnesia at concentrations well below those that cause loss of consciousness and immobility; however, the underlying neuronal mechanisms are unknown. Although many anesthetics increase inhibitory GABAergic synaptic transmission, this effect occurs only at high concentrations (>100 mu M). Molecular targets for low concentrations of inhaled anesthetics have not been identified. Here, we report that a tonic inhibitory conductance in hippocampal pyramidal neurons generated by alpha5 subunit-containing GABA sub(A) receptors is highly sensitive to low concentrations of the volatile anesthetic isoflurane (ISO) (25 and 83.3 mu M). The alpha5 subunit is necessary for enhancement of the tonic current by these low concentrations of isoflurane because potentiation is absent in neurons from alpha5 super(-/-) mice. Furthermore, ISO (25 mu M) potentiated recombinant human alpha5beta3gamma2L GABA sub(A) receptors, whereas this effect was not seen with alpha1beta3gamma2L GABA sub(A) receptors. These studies suggest that an increased tonic inhibition in the hippocampus may contribute to amnestic properties of volatile anesthetics.
Volatile (inhaled) anesthetics cause amnesia at concentrations well below those that cause loss of consciousness and immobility; however, the underlying neuronal mechanisms are unknown. Although many anesthetics increase inhibitory GABAergic synaptic transmission, this effect occurs only at high concentrations (>100 microm). Molecular targets for low concentrations of inhaled anesthetics have not been identified. Here, we report that a tonic inhibitory conductance in hippocampal pyramidal neurons generated by alpha5 subunit-containing GABA(A) receptors is highly sensitive to low concentrations of the volatile anesthetic isoflurane (ISO) (25 and 83.3 microm). The alpha5 subunit is necessary for enhancement of the tonic current by these low concentrations of isoflurane because potentiation is absent in neurons from alpha5-/- mice. Furthermore, ISO (25 microm) potentiated recombinant human alpha5beta3gamma2L GABA(A) receptors, whereas this effect was not seen with alpha1beta3gamma2L GABA(A) receptors. These studies suggest that an increased tonic inhibition in the hippocampus may contribute to amnestic properties of volatile anesthetics.Volatile (inhaled) anesthetics cause amnesia at concentrations well below those that cause loss of consciousness and immobility; however, the underlying neuronal mechanisms are unknown. Although many anesthetics increase inhibitory GABAergic synaptic transmission, this effect occurs only at high concentrations (>100 microm). Molecular targets for low concentrations of inhaled anesthetics have not been identified. Here, we report that a tonic inhibitory conductance in hippocampal pyramidal neurons generated by alpha5 subunit-containing GABA(A) receptors is highly sensitive to low concentrations of the volatile anesthetic isoflurane (ISO) (25 and 83.3 microm). The alpha5 subunit is necessary for enhancement of the tonic current by these low concentrations of isoflurane because potentiation is absent in neurons from alpha5-/- mice. Furthermore, ISO (25 microm) potentiated recombinant human alpha5beta3gamma2L GABA(A) receptors, whereas this effect was not seen with alpha1beta3gamma2L GABA(A) receptors. These studies suggest that an increased tonic inhibition in the hippocampus may contribute to amnestic properties of volatile anesthetics.
Volatile (inhaled) anesthetics cause amnesia at concentrations well below those that cause loss of consciousness and immobility; however, the underlying neuronal mechanisms are unknown. Although many anesthetics increase inhibitory GABAergic synaptic transmission, this effect occurs only at high concentrations (>100 microm). Molecular targets for low concentrations of inhaled anesthetics have not been identified. Here, we report that a tonic inhibitory conductance in hippocampal pyramidal neurons generated by alpha5 subunit-containing GABA(A) receptors is highly sensitive to low concentrations of the volatile anesthetic isoflurane (ISO) (25 and 83.3 microm). The alpha5 subunit is necessary for enhancement of the tonic current by these low concentrations of isoflurane because potentiation is absent in neurons from alpha5-/- mice. Furthermore, ISO (25 microm) potentiated recombinant human alpha5beta3gamma2L GABA(A) receptors, whereas this effect was not seen with alpha1beta3gamma2L GABA(A) receptors. These studies suggest that an increased tonic inhibition in the hippocampus may contribute to amnestic properties of volatile anesthetics.
Volatile (inhaled) anesthetics cause amnesia at concentrations well below those that cause loss of consciousness and immobility; however, the underlying neuronal mechanisms are unknown. Although many anesthetics increase inhibitory GABAergic synaptic transmission, this effect occurs only at high concentrations (>100 μ m ). Molecular targets for low concentrations of inhaled anesthetics have not been identified. Here, we report that a tonic inhibitory conductance in hippocampal pyramidal neurons generated by α5 subunit-containing GABA A receptors is highly sensitive to low concentrations of the volatile anesthetic isoflurane (ISO) (25 and 83.3 μ m ). The α5 subunit is necessary for enhancement of the tonic current by these low concentrations of isoflurane because potentiation is absent in neurons from α5 -/- mice. Furthermore, ISO (25 μ m ) potentiated recombinant human α5β3γ2L GABA A receptors, whereas this effect was not seen with α1β3γ2L GABA A receptors. These studies suggest that an increased tonic inhibition in the hippocampus may contribute to amnestic properties of volatile anesthetics.
Author Orser, Beverley A
Elliott, Erin M
Wafford, Keith A
You-Ten, Kong E
Rosahl, Thomas W
Newell, J. Glen
MacDonald, John F
Caraiscos, Valerie B
Author_xml – sequence: 1
  fullname: Caraiscos, Valerie B
– sequence: 2
  fullname: Newell, J. Glen
– sequence: 3
  fullname: You-Ten, Kong E
– sequence: 4
  fullname: Elliott, Erin M
– sequence: 5
  fullname: Rosahl, Thomas W
– sequence: 6
  fullname: Wafford, Keith A
– sequence: 7
  fullname: MacDonald, John F
– sequence: 8
  fullname: Orser, Beverley A
BackLink https://www.ncbi.nlm.nih.gov/pubmed/15456818$$D View this record in MEDLINE/PubMed
BookMark eNqFUk1vEzEUtFARTQt_ofIJTlv8tfZaQkghCm1QaCXacrWcjTdr5LVTe7dRfwT_GS8pEXDp6VnvzYzn2XMCjnzwBoAzjM5xSej7L1fzu2_XN7PFOUGcFojlitgLMMlTWRCG8BGYICJQwZlgx-AkpR8IIYGweAWOcclKXuFqAn7eGGfq3j4YOPet9rXpjO9haOBt8LaGF9NPUxM3-bTwrV3Z3gYPrYdfh2i9gZd2uw217rbawSszxOATXD3CZdjBWchivo96pKRRsW8N_B5cbjgDp96k3OhH5RQaN0TtzWvwstEumTdP9RTcfZ7fzi6L5fXFYjZdFnVJZV-smS6FJEJgzdla8IrUFaeaywZr0jC50rLSnNKGEomNQHVD-IqxNTeClrhZ01Pwca-7HVadWe99OrWNttPxUQVt1b8Tb1u1CQ-KCyIlolng7ZNADPdD3kR1NtXGubxEGJLiXFJCMHsWiIWQlFKZgWd_Wzp4-fNVGfBhD6hjSCmaRtW2__242aF1CiM1JkMdkqHGZCjE1JiMTOf_0Q83PEd8tye2dtPubDQqddq5bBOr3W5HmKJSVaxk9BdbLM4R
CitedBy_id crossref_primary_10_1042_BST0371334
crossref_primary_10_1097_ALN_0000000000004949
crossref_primary_10_1056_NEJMe0800998
crossref_primary_10_1007_s12630_012_9749_x
crossref_primary_10_1523_JNEUROSCI_0344_13_2013
crossref_primary_10_1016_j_eplepsyres_2005_12_001
crossref_primary_10_1038_npp_2009_57
crossref_primary_10_1074_jbc_M110_149229
crossref_primary_10_1007_s12630_010_9414_1
crossref_primary_10_1016_j_neuropharm_2008_08_010
crossref_primary_10_1097_ALN_0000000000002881
crossref_primary_10_1016_j_pbb_2007_12_011
crossref_primary_10_1371_journal_pone_0072976
crossref_primary_10_1093_bja_aet038
crossref_primary_10_2174_1570159X19666210215120755
crossref_primary_10_1097_ALN_0000000000000943
crossref_primary_10_1111_j_1471_4159_2006_04055_x
crossref_primary_10_1124_jpet_106_106260
crossref_primary_10_1016_j_ics_2005_06_085
crossref_primary_10_1016_j_neulet_2009_08_041
crossref_primary_10_1038_nrn1625
crossref_primary_10_1073_pnas_0604304103
crossref_primary_10_1523_JNEUROSCI_5024_05_2006
crossref_primary_10_1016_j_ejphar_2013_09_018
crossref_primary_10_1016_j_neuropharm_2010_11_016
crossref_primary_10_1093_bja_aex199
crossref_primary_10_4097_kjae_2010_59_1_3
crossref_primary_10_1007_s12035_023_03574_7
crossref_primary_10_1016_j_neuropharm_2014_08_003
crossref_primary_10_1016_j_neuropharm_2007_11_001
crossref_primary_10_1016_j_ejphar_2024_176561
crossref_primary_10_1016_j_nbd_2017_01_009
crossref_primary_10_3389_fnsys_2017_00058
crossref_primary_10_1021_jm2001597
crossref_primary_10_1210_en_2010_1191
crossref_primary_10_1016_j_ics_2005_07_077
crossref_primary_10_2174_1570159X19666210803105232
crossref_primary_10_1016_j_brainresbull_2015_09_001
crossref_primary_10_1007_s12035_013_8548_x
crossref_primary_10_1016_j_tips_2005_08_006
crossref_primary_10_1016_j_neuropharm_2023_109587
crossref_primary_10_1152_jn_01199_2005
crossref_primary_10_1002_jnr_21991
crossref_primary_10_1016_j_neuropharm_2017_07_027
crossref_primary_10_1016_j_neuroscience_2010_09_034
crossref_primary_10_1016_j_ics_2005_07_070
crossref_primary_10_1093_cercor_bhj055
crossref_primary_10_1093_cercor_bhq169
crossref_primary_10_4097_kjae_2009_56_6_675
crossref_primary_10_1016_j_pharmthera_2005_05_009
crossref_primary_10_1152_jn_00482_2007
crossref_primary_10_1213_ANE_0000000000001403
crossref_primary_10_1213_ane_0b013e3181904571
crossref_primary_10_1213_ANE_0b013e3181bf6ae6
crossref_primary_10_1016_j_ebiom_2021_103272
crossref_primary_10_1038_s41467_024_48489_6
crossref_primary_10_1016_j_brainres_2009_06_058
crossref_primary_10_1111_j_1476_5381_2011_01604_x
crossref_primary_10_1097_ALN_0000000000001861
crossref_primary_10_1186_1471_2202_5_52
crossref_primary_10_1523_JNEUROSCI_4702_05_2006
crossref_primary_10_1021_pr060311u
crossref_primary_10_1016_j_phrs_2017_12_031
crossref_primary_10_1097_ALN_0b013e31828e180e
crossref_primary_10_1111_j_1476_5381_2011_01690_x
crossref_primary_10_1016_j_bja_2020_07_054
crossref_primary_10_3390_ph3113461
crossref_primary_10_1016_j_neuropharm_2017_04_002
crossref_primary_10_1038_nrn2372
crossref_primary_10_1093_bja_aen036
crossref_primary_10_4103_1673_5374_250621
crossref_primary_10_1097_01_aco_0000174961_90135_dc
crossref_primary_10_1097_ALN_0000000000002380
crossref_primary_10_1124_jpet_107_134569
crossref_primary_10_1016_j_pharmthera_2007_03_004
crossref_primary_10_1007_s10877_006_9044_x
crossref_primary_10_1093_bja_aet177
crossref_primary_10_3389_fnagi_2021_802582
crossref_primary_10_1016_j_pharmthera_2005_12_005
crossref_primary_10_1097_ALN_0000000000003798
crossref_primary_10_1016_j_brainresbull_2012_08_001
crossref_primary_10_1111_cns_14716
crossref_primary_10_1016_j_neuropharm_2008_11_002
crossref_primary_10_1213_ANE_0b013e3182291782
crossref_primary_10_2174_1568026619666191114101425
crossref_primary_10_1152_jn_90484_2008
crossref_primary_10_1097_ACO_0000000000000358
crossref_primary_10_1172_JCI63375
crossref_primary_10_1152_jn_00405_2005
crossref_primary_10_1213_ane_0b013e31818d8b79
crossref_primary_10_1111_j_1472_8206_2008_00657_x
crossref_primary_10_1523_JNEUROSCI_3340_09_2009
crossref_primary_10_1016_j_neulet_2013_05_040
crossref_primary_10_1097_01_ASM_0001077436_47894_20
crossref_primary_10_2174_1570159X18666200227125854
Cites_doi 10.1097/00000542-200103000-00020
10.1016/S0028-3908(01)00189-7
10.1016/S0166-2236(96)80023-3
10.1016/S0165-6147(99)01405-4
10.1093/bja/71.1.65
10.1038/38738
10.1073/pnas.0307231101
10.1124/mol.59.4.814
10.1097/00000539-199602000-00019
10.1097/00000542-199211000-00009
10.1002/cne.903590111
10.1124/mol.53.3.530
10.1152/jn.00856.2002
10.1111/j.1460-9568.1997.tb01630.x
10.1097/00000542-200103000-00024
10.1002/cne.10102
10.1097/00000542-196511000-00010
10.1097/00000542-200208000-00023
10.1124/mol.63.1.2
10.1016/j.tins.2004.03.005
10.1097/00000542-200110000-00018
10.1097/00000542-199901000-00018
10.1056/NEJMra021261
10.1152/jn.1993.70.4.1339
10.1016/0278-5846(89)90135-8
10.1016/S0378-4274(98)00158-1
10.1523/JNEUROSCI.22-13-05572.2002
10.1016/0006-8993(86)91230-8
10.1073/pnas.142288699
10.1152/jn.00223.2004
10.1096/fasebj.9.14.7589987
10.1016/S0301-0082(02)00013-8
ContentType Journal Article
Copyright Copyright © 2004 Society for Neuroscience 0270-6474/04/248454-05.00/0 2004
Copyright_xml – notice: Copyright © 2004 Society for Neuroscience 0270-6474/04/248454-05.00/0 2004
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7TK
7X8
5PM
DOI 10.1523/JNEUROSCI.2063-04.2004
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Neurosciences Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Neurosciences Abstracts
MEDLINE - Academic
DatabaseTitleList Neurosciences Abstracts
MEDLINE - Academic
MEDLINE

CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
EISSN 1529-2401
EndPage 8458
ExternalDocumentID PMC6729903
15456818
10_1523_JNEUROSCI_2063_04_2004
www24_39_8454
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID -
08R
2WC
34G
39C
3O-
53G
55
5GY
5RE
5VS
ABFLS
ABIVO
ABPTK
ABUFD
ACNCT
ADACO
ADBBV
ADCOW
AENEX
AETEA
AFFNX
AFMIJ
AIZTS
AJYGW
ALMA_UNASSIGNED_HOLDINGS
BAWUL
CS3
DIK
DL
DU5
DZ
E3Z
EBS
EJD
F5P
FA8
FH7
GJ
GX1
H13
HYE
H~9
KQ8
L7B
MVM
O0-
OK1
P0W
P2P
QZG
R.V
RHF
RHI
RIG
RPM
TFN
UQL
VH1
WH7
WOQ
X
X7M
XJT
ZA5
ZGI
ZXP
---
-DZ
-~X
.55
.GJ
18M
AAFWJ
AAJMC
AAYXX
ABBAR
ACGUR
ADHGD
ADXHL
AFCFT
AFOSN
AFSQR
AHWXS
AI.
AOIJS
BTFSW
CITATION
TR2
W8F
YBU
YHG
YKV
YNH
YSK
AFHIN
CGR
CUY
CVF
ECM
EIF
NPM
7TK
7X8
5PM
ID FETCH-LOGICAL-c539t-d4a5792771a64d7682c863a69f1a2f49ba98a633f3291e70cf26b44d6e7351fd3
ISSN 0270-6474
1529-2401
IngestDate Thu Aug 21 18:27:22 EDT 2025
Fri Jul 11 10:17:41 EDT 2025
Fri Jul 11 09:48:40 EDT 2025
Wed Feb 19 02:34:34 EST 2025
Tue Jul 01 00:49:03 EDT 2025
Thu Apr 24 22:55:01 EDT 2025
Tue Nov 10 19:18:23 EST 2020
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 39
Language English
License https://creativecommons.org/licenses/by-nc-sa/4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c539t-d4a5792771a64d7682c863a69f1a2f49ba98a633f3291e70cf26b44d6e7351fd3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
OpenAccessLink https://www.jneurosci.org/content/jneuro/24/39/8454.full.pdf
PMID 15456818
PQID 17793339
PQPubID 23462
PageCount 5
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_6729903
proquest_miscellaneous_66932214
proquest_miscellaneous_17793339
pubmed_primary_15456818
crossref_citationtrail_10_1523_JNEUROSCI_2063_04_2004
crossref_primary_10_1523_JNEUROSCI_2063_04_2004
highwire_smallpub1_www24_39_8454
ProviderPackageCode RHF
RHI
CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20040929
2004-09-29
2004-Sep-29
PublicationDateYYYYMMDD 2004-09-29
PublicationDate_xml – month: 09
  year: 2004
  text: 20040929
  day: 29
PublicationDecade 2000
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle The Journal of neuroscience
PublicationTitleAlternate J Neurosci
PublicationYear 2004
Publisher Soc Neuroscience
Society for Neuroscience
Publisher_xml – name: Soc Neuroscience
– name: Society for Neuroscience
References (2023041303085055000_24.39.8454.28) 1994; 46
(2023041303085055000_24.39.8454.20) 1993; 70
2023041303085055000_24.39.8454.4
2023041303085055000_24.39.8454.3
2023041303085055000_24.39.8454.2
2023041303085055000_24.39.8454.1
2023041303085055000_24.39.8454.7
2023041303085055000_24.39.8454.6
2023041303085055000_24.39.8454.5
2023041303085055000_24.39.8454.29
2023041303085055000_24.39.8454.27
2023041303085055000_24.39.8454.26
2023041303085055000_24.39.8454.25
2023041303085055000_24.39.8454.13
2023041303085055000_24.39.8454.35
2023041303085055000_24.39.8454.12
2023041303085055000_24.39.8454.34
2023041303085055000_24.39.8454.11
2023041303085055000_24.39.8454.33
2023041303085055000_24.39.8454.10
(2023041303085055000_24.39.8454.31) 2002; 97
2023041303085055000_24.39.8454.32
2023041303085055000_24.39.8454.30
(2023041303085055000_24.39.8454.15) 1998; 100-101
(2023041303085055000_24.39.8454.8) 2002; 22
(2023041303085055000_24.39.8454.18) 1995; 9
(2023041303085055000_24.39.8454.19) 2001; 21
(2023041303085055000_24.39.8454.9) 1978; 57
2023041303085055000_24.39.8454.16
2023041303085055000_24.39.8454.14
2023041303085055000_24.39.8454.36
2023041303085055000_24.39.8454.24
(2023041303085055000_24.39.8454.17) 1943; 22
2023041303085055000_24.39.8454.23
2023041303085055000_24.39.8454.22
(2023041303085055000_24.39.8454.21) 2001; 94
References_xml – volume: 94
  start-page: 478
  year: 2001
  ident: 2023041303085055000_24.39.8454.21
  publication-title: Anesthesiology
  doi: 10.1097/00000542-200103000-00020
– ident: 2023041303085055000_24.39.8454.30
  doi: 10.1016/S0028-3908(01)00189-7
– ident: 2023041303085055000_24.39.8454.27
  doi: 10.1016/S0166-2236(96)80023-3
– ident: 2023041303085055000_24.39.8454.3
  doi: 10.1016/S0165-6147(99)01405-4
– ident: 2023041303085055000_24.39.8454.14
  doi: 10.1093/bja/71.1.65
– ident: 2023041303085055000_24.39.8454.29
  doi: 10.1038/38738
– ident: 2023041303085055000_24.39.8454.7
  doi: 10.1073/pnas.0307231101
– ident: 2023041303085055000_24.39.8454.1
  doi: 10.1124/mol.59.4.814
– ident: 2023041303085055000_24.39.8454.22
  doi: 10.1097/00000539-199602000-00019
– ident: 2023041303085055000_24.39.8454.12
  doi: 10.1097/00000542-199211000-00009
– ident: 2023041303085055000_24.39.8454.16
  doi: 10.1002/cne.903590111
– ident: 2023041303085055000_24.39.8454.24
  doi: 10.1124/mol.53.3.530
– ident: 2023041303085055000_24.39.8454.35
  doi: 10.1152/jn.00856.2002
– volume: 21
  start-page: 1
  year: 2001
  ident: 2023041303085055000_24.39.8454.19
  publication-title: J Neurosci
– ident: 2023041303085055000_24.39.8454.34
  doi: 10.1111/j.1460-9568.1997.tb01630.x
– ident: 2023041303085055000_24.39.8454.11
  doi: 10.1097/00000542-200103000-00024
– ident: 2023041303085055000_24.39.8454.5
  doi: 10.1002/cne.10102
– ident: 2023041303085055000_24.39.8454.13
  doi: 10.1097/00000542-196511000-00010
– volume: 97
  start-page: 447
  year: 2002
  ident: 2023041303085055000_24.39.8454.31
  publication-title: Anesthesiology
  doi: 10.1097/00000542-200208000-00023
– ident: 2023041303085055000_24.39.8454.36
  doi: 10.1124/mol.63.1.2
– volume: 46
  start-page: 851
  year: 1994
  ident: 2023041303085055000_24.39.8454.28
  publication-title: Mol Pharmacol
– ident: 2023041303085055000_24.39.8454.32
  doi: 10.1016/j.tins.2004.03.005
– ident: 2023041303085055000_24.39.8454.33
  doi: 10.1097/00000542-200110000-00018
– volume: 57
  start-page: 434
  year: 1978
  ident: 2023041303085055000_24.39.8454.9
  publication-title: Anesth Analg
– ident: 2023041303085055000_24.39.8454.2
  doi: 10.1097/00000542-199901000-00018
– ident: 2023041303085055000_24.39.8454.6
  doi: 10.1056/NEJMra021261
– volume: 70
  start-page: 1339
  year: 1993
  ident: 2023041303085055000_24.39.8454.20
  publication-title: J Neurophysiol
  doi: 10.1152/jn.1993.70.4.1339
– ident: 2023041303085055000_24.39.8454.26
  doi: 10.1016/0278-5846(89)90135-8
– volume: 100-101
  start-page: 1
  year: 1998
  ident: 2023041303085055000_24.39.8454.15
  publication-title: Toxicol Lett
  doi: 10.1016/S0378-4274(98)00158-1
– volume: 22
  start-page: 5572
  year: 2002
  ident: 2023041303085055000_24.39.8454.8
  publication-title: J Neurosci
  doi: 10.1523/JNEUROSCI.22-13-05572.2002
– ident: 2023041303085055000_24.39.8454.25
  doi: 10.1016/0006-8993(86)91230-8
– volume: 22
  start-page: 275
  year: 1943
  ident: 2023041303085055000_24.39.8454.17
  publication-title: Anesth Analg
– ident: 2023041303085055000_24.39.8454.10
  doi: 10.1073/pnas.142288699
– ident: 2023041303085055000_24.39.8454.4
  doi: 10.1152/jn.00223.2004
– volume: 9
  start-page: 1454
  year: 1995
  ident: 2023041303085055000_24.39.8454.18
  publication-title: FASEB J
  doi: 10.1096/fasebj.9.14.7589987
– ident: 2023041303085055000_24.39.8454.23
  doi: 10.1016/S0301-0082(02)00013-8
SSID ssj0007017
Score 2.1827965
Snippet Volatile (inhaled) anesthetics cause amnesia at concentrations well below those that cause loss of consciousness and immobility; however, the underlying...
SourceID pubmedcentral
proquest
pubmed
crossref
highwire
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 8454
SubjectTerms Anesthetics, Inhalation - pharmacology
Animals
Brief Communications
Cells, Cultured
Cerebral Cortex - cytology
Dose-Response Relationship, Drug
Evoked Potentials - drug effects
Excitatory Postsynaptic Potentials - drug effects
Hippocampus - cytology
Hippocampus - drug effects
Hippocampus - physiology
Isoflurane - pharmacology
Mice
Mice, Knockout
Neural Inhibition - drug effects
Pyramidal Cells - drug effects
Pyramidal Cells - physiology
Receptors, GABA-A - drug effects
Receptors, GABA-A - genetics
Receptors, GABA-A - physiology
Recombinant Proteins
Synaptic Transmission - drug effects
Title Selective Enhancement of Tonic GABAergic Inhibition in Murine Hippocampal Neurons by Low Concentrations of the Volatile Anesthetic Isoflurane
URI http://www.jneurosci.org/cgi/content/abstract/24/39/8454
https://www.ncbi.nlm.nih.gov/pubmed/15456818
https://www.proquest.com/docview/17793339
https://www.proquest.com/docview/66932214
https://pubmed.ncbi.nlm.nih.gov/PMC6729903
Volume 24
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jj9MwFLbKcAUBw1JWHxCXKjNZnKQ5ljL7UA7Tot6sOInVSGlSdVE1_Ad-A3-V9-xshaIBLlHkZmu-L2-x30LIezuWURJKYcRu5BrMDS1DgFUMgIBvYMq-0N0bPo-88wm7nLrTTudHK2ppsxZH0be9eSX_gyqMAa6YJfsPyNYXhQHYB3xhCwjD9q8wvlFNbDD2J8lnCF-1sr9WfW3OBh8HyRJEWy_NZ6lIq7jGOc6wY6nhxQI0GciDrKfKWuYrNEazYoux6Dpqs46TQ_sUJBkMZLjgALpkhumPvXRVyGwDCm8npKhJOFOmbqtoZs2jYbgM01Wko_y-gpoCn71pAQ2ytwq_6Z1lTboaCCdjrCXlFXZJqvMoWrEnINrzcpK3ms5gGHtRznmUEthWSz6acMmesVJs69Trkp66IFIphPtM16X-TTu4qkrF5QiDJG-GF0e2iYvYamaNNfqwigEYfeGnk-trPj6Zju-R-zb4Idgi49PFVa3qfVO1dK6fr0xBh_sc77_LrvVTVaTe5938GqTbsnrGj8jDEkM60Nx7TDpJ_oQcDvJwXcxv6QeqAojVyswh-V7TkbboSAtJFR1pTUfa0BF2qaYjbdGRlnSk4pYCHekuHdUVZwmt6EgbOtKGjk_J5PRkPDw3ym4fRuQ6wdqIWej6AbxlK_RYDF6wHfU9J_QCaYW2ZIEIg37oOY507MBKfDOSticYi73Ed1xLxs4zcpAXefKCUBZYjhACRA2TzDWl8PoCdJcZB7GwXMm6xK1Q4FFZCh87smQcXWJAj9focUSPmwzbtcJ5x_V5C10M5s4zaAUyX83DLANMLb7dbm3GnYAjU7vkXQU-B9GO63XwkorNils-KE_HCf58hOeB-2VbcI3nmizNY6FnBMZ4l_g7NKoPwLLyu7_k6UyVl_d8NFGdl3fe9RV5gP9Rf8U4KfmaHKyXm-QNmOlr8VZ9Kj8B7RHuGA
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Selective+enhancement+of+tonic+GABAergic+inhibition+in+murine+hippocampal+neurons+by+low+concentrations+of+the+volatile+anesthetic+isoflurane&rft.jtitle=The+Journal+of+neuroscience&rft.au=Caraiscos%2C+Valerie+B&rft.au=Newell%2C+J+Glen&rft.au=You-Ten%2C+Kong+E&rft.au=Elliott%2C+Erin+M&rft.date=2004-09-29&rft.issn=1529-2401&rft.eissn=1529-2401&rft.volume=24&rft.issue=39&rft.spage=8454&rft_id=info:doi/10.1523%2FJNEUROSCI.2063-04.2004&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0270-6474&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0270-6474&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0270-6474&client=summon